Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced that five internationally renowned experts, from Israel and the world, have joined its scientific board and team of consultants. The new experts will join Prof. Raphael Mechoulam, who identified the active compound in cannabis, THC, on the advisory board, and
Dr. Yafit Stark, a vice president at Teva and a member of the Company’s Board of Directors. Such experts will assist the Company by providing counsel, planning and executing the clinical trials for which the Company is preparing.
The experts joining the Company include:
Prof. James Leckman, a child psychiatrist, psychiatrist and physician at Yale University. Dr. Leckman is a reputable child psychiatrist and patient-oriented clinical researcher. He served as Director of the Child Study Center at Yale for over two decades. His colleagues have chosen him as one of the best doctors in America. Prof. Leckman is one of the prominent and notable international experts in the field of research and treatment of Tourette syndrome and movement disorders, and is the author of hundreds of publications in books and leading journals.
Prof. Kirsten Müller-Vahl, Professor of Psychiatry at the Department of Psychiatry, Socialpsychiatry and Psychotherapy of the Hannover Medical School, Germany. An expert in neurology and an adult psychiatrist, who has been working for many years in a clinic specializing in movement disorders. Since 1997 and until 2003, she was the recipient of an award from the German government for clinical research related to Tourette syndrome. In the course of the past
18 years, Prof. Müller-Vahl has studied more than 1,200 adults and children suffering from Tourette and has served as Head of a Tourette syndrome outpatient department since 1995. Since 1994, she has been serving as a member of the scientific advisory board of the German TouretteSyndrome Association. Prof. Müller-Vahl is the world’s leading researcher in the field of cannabinoid-use in treating patients with Tourette syndrome.
Prof. Michael Davidson, Professor of Psychiatry, served as Chief Psychiatrist at the Department of Psychiatry of the Sheba Medical Centre Tel-Hashomer between 2001 and 2007, and currently serves, inter alia, as Chairman of the Stuckinski Centre for Alzheimer’s Disease Research in Ramat Gan. He holds a professorship at the Sackler School of Medicine Tel Aviv University and at the Mount Sinai School of Medicine in New York. Prof. Davidson is considered an international expert on Alzheimer’s Disease and is the author of approximately 300 publications in scientific literature. He is also the editor of European Neuropsychopharmacology.
Prof. Avi Weizman, Professor of Psychiatry at the Sackler School of Medicine Tel Aviv University, Head of the Laboratory of Biological Psychiatry at the Felsentein Medical Research Center and Director of the Center and Head of Geha Mental Health Center's Research Unit. After earning his MD, he pursued a postgraduate fellowship in both Child and Adult Psychiatry at Tel Aviv University. Since graduating, he held several academic, research, clinical and administrative positions at both Tel Aviv University and the Geha Mental Health Center. Prof. Weizman is an international expert in psychiatry and neuroscience and is the author of 5 books and more that 650 publications in scientific literature.
Dr. Michael Bloch, graduated the Yale University School of Medicine and completed his residency in adult and child psychiatry at Yale. Dr. Bloch serves as Chief Resident at Yale’s Clinical Neuroscience Research Unit. His fields of research are concentrated on the study of Tourette syndrome, obsessive-compulsive disorder and trichotillomania across the life span. His research focuses on developing better treatments for children and adults in such situations, and examining predictions of long-term outcomes, with an emphasis on neuroimaging.
Dr. Elran Haber, Therapix’s CEO, stated that “we welcome the joining of the revered team of experts, and believe, that in light of their scientific achievements, proficiency and vast accumulated experience, their joining will contribute to the promotion of the Company’s operations and the advancement of its business and scientific objectives”.
Therapix is an Israeli pharma company specializing in the development and commercialization of approved drugs that are based on cannabinoid molecules. The Company is listed on the Tel Aviv Stock Exchange and is also traded over-the counter (OTC) in the United States. The Company is engaged in the development of a drug based on cannabinoids and the entourage technology for treating Tourette syndrome, and is preparing for the development of a cannabinoid-based drug for treating impairments in cognitive functioning (including preliminary stages of Alzheimer’s disease). The Company’s Chairman is Dr. Ascher Shmulewitz and Dr. Elran Haber is its CEO.
For further details, Goldfinger Communications, Irit Radia, 054-6699311